Prognostic and predictive impact of molecular tumor burden index in non-small cell lung cancer patients.

ABSTRACT:

Background

The biomarkers of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC) patients have limited predictive performance. In this study we aimed to investigate the feasibility of molecular tumor burden index (mTBI) in circulating tumor DNA (ctDNA) as a predictor for immunotherapy in patients with NSCLC.

Methods

From February 2017 to November 2020, pretreatment and on-treatment (3~6 weeks after first cycle of immunotherapy) dynamic plasma ctDNA samples from NSCLC patients receiving immune monotherapy or combination therapy were analyzed by targeted capture sequencing of 1021 genes. PyClone was used to infer the mTBI. The impact of pretreatment mTBI on survival outcomes was verified in the POPLAR/OAK trials.

Results

We found that pat

SUBMITTER: Yang F 

PROVIDER: S-EPMC10626252 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature